Back to today’s briefing

Story perspectives

Generic Lenacapavir to Cost Just $40 Annually by 2027

9/28/2025

27 5

Summary

Story summary

Dr. Reddy’s Laboratories and Hetero Labs will sell generic lenacapavir for $40 annually beginning in 2027 to expand access in low- and middle-income countries.
Developed by Gilead Sciences, lenacapavir is a twice-yearly injection that prevents HIV.
The U.S. branded version costs about $28,000 annually, highlighting generics’ affordability.
Unitaid and the Gates Foundation back the effort to expand access.

1 of 1

Story summary

Dr. Reddy’s Laboratories and Hetero Labs will sell generic lenacapavir for $40 annually beginning in 2027 to expand access in low- and middle-income countries.
Developed by Gilead Sciences, lenacapavir is a twice-yearly injection that prevents HIV.
The U.S. branded version costs about $28,000 annually, highlighting generics’ affordability.
Unitaid and the Gates Foundation back the effort to expand access.